Pharming Ebit Per Revenue from 2010 to 2024

PHAR Stock  USD 8.98  0.34  3.65%   
Pharming Group Ebit Per Revenue yearly trend continues to be relatively stable with very little volatility. Ebit Per Revenue is likely to drop to -0.02. During the period from 2010 to 2024, Pharming Group Ebit Per Revenue destribution of quarterly values had range of 45.8937 from its regression line and mean deviation of  5.92. View All Fundamentals
 
Ebit Per Revenue  
First Reported
2010-12-31
Previous Quarter
(0.02)
Current Value
(0.02)
Quarterly Volatility
11.70477172
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 16.7 M, Interest Expense of 6.4 M or Selling And Marketing Expenses of 6.5 M, as well as many indicators such as Price To Sales Ratio of 3.62, Dividend Yield of 0.0 or PTB Ratio of 3.92. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
  
Check out the analysis of Pharming Group Correlation against competitors.

Latest Pharming Group's Ebit Per Revenue Growth Pattern

Below is the plot of the Ebit Per Revenue of Pharming Group NV over the last few years. It is Pharming Group's Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
Ebit Per Revenue10 Years Trend
Slightly volatile
   Ebit Per Revenue   
       Timeline  

Pharming Ebit Per Revenue Regression Statistics

Arithmetic Mean(3.65)
Geometric Mean0.42
Coefficient Of Variation(321.01)
Mean Deviation5.92
Median(0.02)
Standard Deviation11.70
Sample Variance137.00
Range45.8937
R-Value0.51
Mean Square Error109.21
R-Squared0.26
Significance0.05
Slope1.33
Total Sum of Squares1,918

Pharming Ebit Per Revenue History

2024 -0.0209
2023 -0.0199
2022 0.0887
2021 0.15
2019 0.36
2018 0.28
2017 0.24

About Pharming Group Financial Statements

Pharming Group shareholders use historical fundamental indicators, such as Ebit Per Revenue, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Ebit Per Revenue(0.02)(0.02)

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.